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H I G H L I G H T S
• Intravenous citalopram acutely elicited brain activation in several regions involved in serotonergic neurotransmission.
• Acute citalopram challenge produced a chemically-induced brain state similar to increased arousal.
• Signiﬁcant dose-dependent activation was demonstrated in the middle cingulate gyrus, a region with neuroticism-related functions.
• The neuroticism personality trait was associated with the individual responses to citalopram challenge.
• These results may further support the modulating eﬀects of serotonin on processing environmental stressors.
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A B S T R A C T
Background: The initial eﬀects of selective serotonin reuptake inhibitors (SSRIs) in the human living brain are
poorly understood. We carried out a 3T resting state fMRI study with pharmacological challenge to determine
the brain activation changes over time following diﬀerent dosages of citalopram.
Methods: During the study, 7.5 mg i.v. citalopram was administered to 32 healthy subjects. In addition, 11.25 mg
citalopram was administered to a subset of 9 subjects to investigate the dose-response. Associations with neu-
roticism (assessed by the NEO PI-R) of the emerging brain activation to citalopram was also investigated.
Results: Citalopram challenge evoked signiﬁcant activation in brain regions that are part of the default mode
network, the visual network and the sensorimotor network, extending to the thalamus, and midbrain. Most
eﬀects appeared to be dose-dependent and this was statistically signiﬁcant in the middle cingulate gyrus.
Individual citalopram-induced brain responses were positively correlated with neuroticism scores and its sub-
scales in speciﬁc brain areas; anxiety subscale scores in thalamus and midbrain and self-consciousness scores in
middle cingulate gyrus. There were no sex diﬀerences.
Limitations: We investigated only healthy subjects and we used a relatively low sample size in the 11.25mg
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citalopram analysis.
Discussion: Our results suggest that SSRIs acutely induce an increased arousal-like state of distributed cortical
and subcortical systems that is mediated by enhanced serotonin neurotransmission according to levels of neu-
roticism and underpins trait sensitivity to environmental stimuli and stressors. Studies in depression are needed
to determine how therapeutic eﬀects eventually emerge.
1. Introduction
Pharmacological magnetic resonance imaging (phMRI) has become
widely used to follow the eﬀects of drugs in modulating neural in-
formation processing (Anderson et al., 2008; Khalili-Mahani et al.,
2017). Experimental administration of SSRIs has been used to acutely
increase synaptic serotonin content and to observe modulatory eﬀects
on brain responses evoked by cognitive and emotion processing tasks in
phMRI studies (Anderson et al., 2008). For example, following the ﬁrst
study by Del Ben et al., (2005) (Del-Ben et al., 2005), several studies
have reported acute reduction of amygdala activation to viewing fearful
faces in healthy volunteers after a single dose of selective serotonin
reuptake inhibitors (SSRI). In depressed patients, suppression of
amygdala responses to fearful faces occurs early in treatement and
predicts subsequent therapeutic beneﬁt (Anderson et al., 2011;
Godlewska et al., 2012, 2016; Harmer et al., 2006; Klomp et al., 2013;
Murphy et al., 2009). A number of studies have reported modulatory
phMRI eﬀects not only on emotion processing (Anderson et al., 2007,
2011; Harmer et al., 2003; Pringle and Harmer, 2015), but also on
reward and punishment sensitivity (Macoveanu, 2014), attention,
memory and response inhibition (Anderson et al., 2008). More recently
a number of studies have described modulation of connectivity in
resting-state networks by SSRIs and other drugs in humans (Klaassens
et al., 2015, 2017, 2018) and rodents (Schaefer et al., 2014; Schwarz
et al., 2009).
SSRI-induced modulation of BOLD responses to cognitive tasks
could result from direct eﬀects of increased synaptic serotonin content
acting on serotonin receptors to alter postsynaptic neuronal activity in
information processing systems. This has led some studies to use chal-
lenge phMRI to follow the direct eﬀects of SSRI-induced enhancement
of extracellular levels of serotonin on regional brain BOLD signals. SSRI
challenge phMRI requires the use of acute intravenous administration
while recording the ensuing BOLD signal changes given that they are
relative, and not absolute, measures. McKie and colleagues reported
increasing BOLD signal following i.v. citalopram in the caudate,
amygdala, hippocampus, striatum and thalamus in 12 healthy male
volunteers compared to i.v. saline (McKie et al., 2005). Similar results
have been observed in rodents (Schwarz et al., 2007; Sekar et al., 2011).
Although this method has the potential to quantify the dynamism of
serotonergic neurotransmission in disorders such as depression, this has
not yet been realised. In this study we determine the replicability of the
McKie paradigm, characterise the time course and dose responsiveness,
and determine whether regional responsiveness relates to the person-
ality trait of neuroticism.
The serotonin transporter, which is the main target of SSRIs, is a key
determinant of brain serotonergic function controlling the duration and
extent of serotonergic neurotransmission (Hariri and Holmes, 2006). In
early life central serotonergic tone modulates development of the sen-
sory system and the corticolimbic circuits (Booij et al., 2015; Gaspar
et al., 2003) that may contribute to behavioural traits such as neuro-
ticism which acts as a vulnerability factor for several neuropsychiatric
disorders (Gaspar et al., 2003; Hariri and Holmes, 2006; Lesch et al.,
1996). Neuroticism is an endophenotype and major risk factor for dis-
orders treated by SSRIs such as anxiety, depression and chronic pain
(Kendler et al., Arch Gen Psychiatry. 2006; Kendler et al., Psychological
Medicine, 2007; Ligthart et al., Twin Res Hum Gen, 2012). Previous
human studies suggested that neuroticism and alterations in emotion
processing were associated with genetically less active serotonin
transporter gene variants (5-HTTLPR) (Hariri and Holmes, 2006; Lesch
et al., 1996; Munafo et al., 2009), although some studies (Middeldorp
et al., 2007; Terracciano et al., 2009; Willis-Owen et al., 2005) and a
large whole genome association study (GWAS) have failed to support
this hypothesis (Smith et al., 2016). One explanation for the incon-
sistent genetic results is that the less active serotonin transporter, pu-
tatively associated with increased synaptic serotonin content, might
amplify processing of both positive and stressful environmental stimuli
as reported in gene-environment interaction studies (Belsky et al.,
2009) and in a human experimental SSRI study (Fox et al., 2011). Si-
milarly, it has been hypothesised that SSRIs acutely facilitate positive
sensory information processing that may be related to their therapeutic
eﬀect (Browning et al., 2007; Castren, 2005, 2013; Harmer et al., 2003;
Harmer and Cowen, 2013). Furthermore, according to the neuroplas-
ticity theory, the therapeutic eﬀect of long-term SSRI treatment is
mediated by changes in synaptic plasticity in interaction with en-
vironmental factors (Kraus et al., 2017; Umemori et al., 2018).
In the present study we used acute intravenous (i.v.) citalopram
challenge to investigate the regional pattern and sequence of brain
activation to increases in synaptic serotonin content. Citalopram is a
highly selective SSRI and the only one available in i.v. form. Previous
studies demonstrated that i.v. administration of citalopram is well tol-
erated, and even a low dose of citalopram leads to a neuroendocrine
response inducing increased plasma prolactin and cortisol levels
(Attenburrow et al., 2001; Lotrich et al., 2005). Based on the previous
results we predicted that using a time-series analysis of BOLD signal
changes from baseline during and after acute i.v. citalopram adminis-
tration (McKie et al., 2005), a dose-dependent increased BOLD signal
would occur in several brain regions involved in sensory information
and in turn emotional information processing.
As previous phMRI studies repeatedly showed that SSRI drugs have
inﬂuence on amygdala function while performing diﬀerent tasks
(Godlewska et al., 2012; Harmer et al., 2006; Murphy et al., 2009) and
in rest (McKie et al., 2005), we made an exploratory analysis of the
BOLD response of amygdala to acute citalopram challenge. In addition
we used a novel data-driven network analysis to identify which regional
BOLD responses relate to neuroticism and its component traits.
2. Material and methods
The Scientiﬁc and Research Ethics Committee of the Medical
Research Council, Budapest, Hungary approved the study. Participants
gave written informed consent after receiving oral and written in-
formation. The work was conducted in accordance with the Declaration
of Helsinki.
2.1. Participants
Thirty-two healthy right-handed volunteers (mean
age ± SD=25.8 ± 4.16 years; 19 female) between 18 and 50 years
of age and recruited through advertisement participated in the study.
Participants were screened for eligibility criteria and underwent a
medical examination (including routine physical, psychiatric and neu-
rological examination, routine blood tests, and ECG carried out by
specialist medical researchers) to determine that they met inclusion and
exclusion criteria. Exclusion criteria were current or past serious med-
ical, neurological and psychiatric disorders and long-term medication
use. Volunteers with any history of psychotropic medication use and
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excessive consumption of alcohol were excluded. All included partici-
pants were healthy and did not take any medication on a regular basis
(oral contraceptives were permitted). Participants were asked to refrain
from any medication for at least 2 days, from alcohol for at least 24 h
and from caﬀeine for at least 4 h before the scanning sessions.
2.2. Self-report measure of personality dimensions
Thirty-one participants (age=26.0 ± 4.24 years; 18 women)
completed the Revised NEO Personality Inventory (NEO PI-R) (Costa
and McCrae, 1992) to assess neuroticism during the screening proce-
dure.
2.3. Experimental design
All participants were invited for two separate scanning sessions
during which phMRI scans were acquired. Anatomical dataset acqui-
sition was performed on the ﬁrst occasion. During two 30-minute
phMRI sessions all participants received normal saline or 7.5mg cita-
lopram infused over 7.5 min in a randomized, balanced-order, double-
blind design. Scanning sessions were separated by at least two weeks.
7.5 mg dose intravenous citalopram was chosen according to a previous
study (McKie et al., 2005). Nine of 32 participants (age=25.9 ± 5.21
years; 6 women) volunteered in an additional experiment and repeated
the drug challenge with 11.25mg citalopram.
Participants were cannulated outside the scanner at least 45min
before they underwent the drug challenge. The baseline saline infusion
lasted 10min at the beginning of the scanning session followed by ci-
talopram or saline infusion for 7.5 min. During the experiment, parti-
cipants rested viewing a blank screen. Every 5min participants rated
their subjective experiences with a yes/no button press for the fol-
lowing statements: anxious, nauseous, drowsy, lightheaded, restless and
uncomfortable. Blood pressure and pulse rate were recorded twice: 2 h
before and 1 h after the phMRI sessions.
2.4. Data acquisition
Functional MRI images were acquired at a 3T MRI scanner (Achieva
3T, Philips Medical System) using an eight-channel SENSE coil and
BOLD-sensitive T2*-weighted echo-planar (EPI) pulse sequence
(TR = 2.500 ms, TE = 30 ms, FOV: 240 × 240 mm2) with
3 mm × 3 mm in-plane resolution and 3 mm slice thickness. The
number of slices was 46 and the EPI sequence length was 1.800 s. A
series of anatomical image acquisitions were made using a T1-weighted
3D TFE sequence with 1 × 1 × 1 mm resolution.
2.5. fMRI data analysis
Imaging data were analysed with Statistical Parametric Mapping
(SPM 12, Friston, The Welcome Department of Cognitive Neurology,
London, UK) using the phMRI analysis method as described by McKie
et al. (2005). SPM uniﬁed segmentation algorithm with default settings
was used for normalisation of the data (Wellcome Department of Ima-
ging Neuroscience, Institute of Neurology, London, UK; http://www.ﬁl.
ion.ucl.ac.uk/spm12/). Images were realigned using the ﬁrst scan as
reference. These realigned images were then segmented based on in-
dividual T1 images and then spatially normalised to MNI space. The
normalised images were smoothened with an 8mm Gaussian kernel.
Additional parameters were made for correction of movement using the
Artifact Detection Tools (ART; http://www.nitrc.org/projects/artifact_
detect/), which were then applied to the ﬁrst level analysis as a re-
gressor.
First level analysis was performed by splitting the phMRI scan into
30 consecutive 1-minute time bins (T01 to 30; averaging over 1-minute
reduces variance while still providing detailed time information of
changes caused by the drug). The images were then normalised by
subtraction of T01 from each subsequent time bin to produce ﬁrst-level
contrast images. The eﬀects of signal drift of the scanner were con-
trolled by modelling the drift in the saline condition across participants.
Then an individually scaled version of the saline drift model was sub-
tracted from each participant's ﬁrst level contrasts. After this step, the
saline time bin images were subtracted from the corresponding citalo-
pram time bin images. We used the baseline time bin (T10) and 20 post-
infusion time bins (T11-T30) for the second-level analysis, as in our
previous studies (Downey et al., 2016; Symonds et al., 2012). For fur-
ther details related to drift correction and baseline selection methods
see Supplementary Materials (Supplementary Figs. 1 and 2 and
Supplementary Tables 1 and 2).
The 21 images were entered into a whole-brain second level re-
peated measure ANOVA using the ﬂexible factorial option in SPM to
investigate time by treatment interaction with time as a repeated
measure factor and F-tests for statistical signiﬁcance (McFarquhar,
2019). To investigate the dose-eﬀect of citalopram, the time bins from
7.5 mg citalopram scans were subtracted from those of 11.25mg cita-
lopram in participants receiving both doses, then these time bins were
also entered into a second level, ﬂexible factorial analysis. To determine
sex diﬀerences in citalopram elicited brain activations, sex as a
grouping factor was entered into the second level repeated measure
ANOVA models using the ﬂexible factorial option in SPM, as described
above. Results of whole-brain analysis are reported with cluster level
Family Wise Error corrected threshold of p(FWE) < 0.05 based on
p < 0.001 uncorrected primary threshold (k≥ 10).
We used a hypothesis-testing ROI analysis to investigate citalopram
eﬀects in the amygdala in view of its role in short- and long-term SSRI
treatment response (Godlewska et al., 2012; Harmer et al., 2006;
Murphy et al., 2009). The amygdala ROI was deﬁned according to
Anatomical Automatic Labeling atlas (Tzourio-Mazoyer et al., 2002),
involving both the left and the right amygdala. Results of ROI analysis
are reported with peak level secondary threshold of p(FWE) < 0.05 at
p < 0.001 uncorrected primary threshold (k≥ 5).
2.6. Statistical analysis of neuroticism and BOLD responses
Spearman's correlation coeﬃcients were used to determine the re-
lationship between activation changes to 7.5mg citalopram and neu-
roticism and its subscales (anxiety, angry-hostility, self-consciousness,
impulsiveness, vulnerability and depression). An overall under the
curve (AUC) BOLD response to citalopram was calculated for each re-
gion in each individual and entered into the correlation matrix. The
AUC was the area of raw signal change values for each individual from
the ﬁnal model of 7.5mg citalopram minus saline analysis at the peak
coordinates within the signiﬁcant clusters. Peak coordinates were de-
termined from the two primary analyses and from the ROI analysis of
amygdala. Namely, we used: a.) peak coordinates within the signiﬁcant
clusters of 7.5 mg citalopram minus saline analysis; b.) peak co-
ordinates within the signiﬁcant clusters of 11.25mg citalopram minus
analysis; and c.) amygdala ROI peak coordinates from the 11.25mg
citalopram minus saline analysis. For further details see Supplementary
Materials. Nominal signiﬁcance was accepted at p= 0.05 level. Bon-
ferroni corrected p values for multiple testing were calculated but
considered too stringent because of interdependences between the re-
ported brain regions and also between the neuroticism total and sub-
scale scores. We therefore applied a graphical LASSO (least absolute
shrinkage and selection operator) based method with adaptive weights
(‘Adalasso’) in order to identify an ‘optimal set’ of relationships (LASSO
coeﬃcients) between investigated variables using the ‘bootnet’ R
package (Epskamp et al., 2017). The Robustmenss (RB) of each coef-
ﬁcient is the number (%) of positive occurrences in 100 diﬀerent
models. For further details related to LASSO method see Supplementary
Materials.
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3. Results
3.1. Behavioural and physiological data
A Wilcoxon signed-rank test showed that the number of ‘yes’ an-
swers to each subjective self-rating did not diﬀer signiﬁcantly between
7.5 mg citalopram and saline sessions in n=32 participants or between
11.25mg and saline sessions in n=9 participants (Table 1). Neither
subjective answers showed any sex diﬀerences.
NEO-PI-R neuroticism scores (mean=81.7 ± 25.34) showed no
sex diﬀerences in our participants (t= 1.684, p=0.103).
There was no eﬀect of either dose of citalopram on heart rate (beats
per minute) or blood pressure (mmHg). For 7.5mg citalopram vs.
saline: heart rate mean diﬀerence=2.9 ± 10.85, t= 1.516,
p=0.140; systolic blood pressure mean diﬀerence=3.9 ± 14.77,
t= 1.449, p= 0.158; and diastolic blood pressure mean diﬀer-
ence= 1.6 ± 12.83, t= 0.716, p=0.479). For 11.25mg citalopram
vs. saline sessions: heart rate mean diﬀerence=−1.1 ± 7.18,
t=−0.464, p=0.655; systolic blood pressure mean diﬀer-
ence=−2.8 ± 12.88, t=−0.647, p= 0.536; diastolic blood pres-
sure mean diﬀerence=−2.0 ± 12.81, t=−0.469, p=0.652).
3.2. 7.5 mg citalopram minus saline analysis
Analysis of 7.5mg citalopram data led to time-dependent eﬀects on
citalopram -saline diﬀrerences in several brain areas within three
clusters; the most extensive activations occurred in the lingual gyrus,
posterior cingulate cortex, the precuneus and the parahippocampal
gyrus. In addition, signiﬁcant activation appeared in two clusters in-
cluding the right postcentral gyrus, left middle temporal and middle
occipital areas (Table 2 and Fig. 1). There was no signiﬁcant diﬀerence
between males and females in the eﬀect of 7.5mg citalopram on whole-
brain BOLD signal changes.
We found no signiﬁcant diﬀerence in BOLD signal responses to
7.5 mg citalopram between the n=9 participants who later received
the higher dose of citalopram, and the other n= 23 participants.
3.3. 11.25 mg citalopram minus saline analysis
Analysis of 11.25mg citalopram minus saline BOLD data revealed
widespread activation in cortical and subcortical structures including
clusters extending to the middle cingulate cortex (MCG), inferior frontal
gyrus, thalamus and midbrain (Table 3, Fig. 2). The caudate, which
showed signiﬁcantly increased activation only at an uncorrected
p < 0.001 threshold in 7.5 mg citalopram minus saline analysis (MNI
coordinates= 9, 11, 2; F= 2.72), was fully FWE-corrected signiﬁcant
in the 11.25mg analysis (Table 2).
3.4. 11.25 mg citalopram minus 7.5 mg citalopram analysis
The dose-eﬀect analysis showed that signiﬁcant time-dependent
BOLD responses to 11.25mg citalopram remained after subtraction of
responses to 7.5 mg in a single cluster extending to the MCG
(size= 103 voxels, MNI coordinates= 24,−16, 35, Peak F= 3.84).
Fig. 3 shows activation changes of the MCG in 7.5 mg citalopram minus
saline and 11.25mg citalopram minus saline analysis over time.
An exploratory analysis of the results with a more lenient threshold
of p < 0.05 with p(FWE) < 0.05 revealed that activation diﬀerences
between the two doses involve extensive brain regions including the
caudate, thalamus and middle frontal gyrus (Supplementary Table 3),




No signiﬁcant eﬀect of 7.5mg citalopram was found in the a priori
bilateral amygdala ROI but 11.25mg evoked signiﬁcant BOLD signal
changes bilaterally compared to saline (right: MNI coordinates= 30,
5,−19, F=4.13, 9 voxels; left: 24,−4,−13, F=3.59, 11 voxels).
Direct comparison of the larger and smaller dose of citalopram showed
no signiﬁcant eﬀect.
Table 1
The results of Wilcoxon signed-rank test of ‘yes’ answers to questions about subjective states between 7.5 mg citalopram and saline sessions and between 11.25 mg
citalopram and saline sessions.
Anxious Drowsy Lightheaded Nauseous Restless Uncomfortable
Z p Z p Z p Z p Z p Z p
7.5mg −1.069 0.285 −1.212 0.226 −1.826 0.068 −1.633 0.102 −0.197 0.844 −0.104 0.917
11.25mg 0.000 1.000 −1.490 0.136 −1.000 0.317 −1.342 0.180 −1.732 0.083 0.000 1.000
Table 2
Areas with signiﬁcant time× treatment interaction from 7.5mg citalopram
minus saline analysis at p(FWE) < 0.05 secondary threshold.




1205 Lingual Gyrus – 4.46 0 −67 5
Lingual Gyrus R 3.56 15 −61 5
Lingual Gyrus L 3.53 −15 −73 23
Posterior Cingulate L 3.40 −9 −55 8
Middle Temporal
Gyrus
R 3.35 39 −64 20
Parahippocampal
Gyrus
R 3.14 15 −46 2
Precuneus R 3.10 9 −73 35
Precuneus – 3.07 0 −70 41
Lingual Gyrus L 3.06 −18 −64 5
Lingual Gyrus R 3.02 21 −67 20
Posterior Cingulate R 2.96 24 −64 17
Cerebellum R 2.90 18 −61 −28
Parahippocampal
Gyrus
R 2.87 30 −46 −10
Parahippocampal
Gyrus
R 2.85 24 −49 −1
Precuneus R 2.81 24 −79 35
Fusiform Gyrus R 2.60 36 −46 −19
175 Postcentral Gyrus R 3.97 36 −34 53
Postcentral Gyrus R 2.91 33 −43 62
177 Middle Temporal
Gyrus
L 3.72 −48 −64 20
Middle Temporal
Gyrus
L 3.63 −45 −70 23
Middle Occipital
Gyrus
L 3.02 −39 −79 5
Middle Temporal
Gyrus
L 2.97 −54 −52 8
Middle Occipital
Gyrus
L 2.75 −48 −70 8
Middle Temporal
Gyrus
L 2.41 −48 −55 2
R= right; L= left; MNI=Montreal Neurological Institute.
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3.5.2. Time-series analysis
Visual inspection showed that the statistically signiﬁcant time-de-
pendent diﬀerences between 7.5mg citalopram and saline is due to a
gradually increasing citalopram-saline diﬀerence. Supplementary Fig. 3
shows the BOLD signal time course in the most signiﬁcant peaks of the 3
clusters, i.e. in the lingual gyrus, in the postcentral gyrus and in the
middle temporal gyrus (MTG). To determine and visualise the order of
the spatiotemporal changes during the 7.5 mg citalopram challenge
paired t-tests were applied to compare successive time bins to the
baseline using the ﬂexible factorial repeated measure ANOVA model.
The ﬁrst signiﬁcant activation change occurred in the occipital cortex
7min after citalopram infusion started (12,−76, 2; T=4.56, 1919
voxels). The activation spread in a posterior-anterior direction, sig-
niﬁcant frontal activation ﬁrst emerging in the medial frontal gyrus
(−12, 59, 26; T= 4.55, 165 voxels) in the 11th minute as the occipital
activation intensiﬁed and spread (−12,−97,−4; T= 5.61, 4340
voxels). The Supplementary video shows the statistically signiﬁcant
BOLD signal changes (t-tests) emerging over 1min time bins from the
onset of the infusion at p < 0.001 primary height threshold without
correction.
3.5.3. Neuroticism-associated changes in brain activity
3.5.3.1. Correlation between neuroticism and citalopram-evoked brain
activation. Neuroticism scores positively correlated with AUC BOLD
responses in thalamus (r= 0.49, p=0.005) and midbrain (r= 0.41,
p=0.021). The strongest and most signiﬁcant correlations were
between the thalamus activation and the anxiety subscale of
neuroticism (r= 0.63, p= 0.0002) and the right MTG and self-
consciousness (r= 0.48, p=0.006). For detailed results, see
Supplementary Table 4 and Supplementary Fig. 4. Using Bonferroni
correction (7 neuroticism scores, 14 brain regions, threshold
p < 0.0005) only the correlation between the thalamus AUC and the
anxiety subscale remained signiﬁcant. However, because of
interdependencies between the investigated variables we used LASSO
method to model our data.
3.5.3.2. LASSO regression analysis of neuroticism scores and citalopram-
evoked brain activation. We modelled the 6 subscales of neuroticism
with sex, age and the BOLD response (AUC) to increased serotonin of
Fig. 1. 7.5 mg citalopram minus saline signiﬁcant time× treatment interaction
at p < 0.001 uncorrected threshold in saggital view.
Table 3
Areas with signiﬁcant time× treatment interaction from 11.25 mg citalopram
minus saline analysis at p(FWE) < 0.05 secondary threshold.






R 4.88 15 −10 35
Middle Cingulate
Gyrus
R 4.76 12 −7 38
101 Fusiform Gyrus R 4.86 45 −49 −22
Fusiform Gyrus R 4.77 39 −55 −19
Fusiform Gyrus R 3.44 33 −43 −19
Cerebellum R 3.19 27 −58 −16
327 Fusiform Gyrus L 4.79 −39 −61 −16
Cerebellum L 4.56 −45 −52 −7
Supramarginal Gyrus L 4.56 −39 −52 32
104 Parahippocampal
gyrus
R 4.31 30 5 −16
Superior Temporal
Gyrus
R 3.95 39 20 −22
Superior Temporal
Gyrus
R 3.84 36 11 −31
Superior Temporal
Gyrus
R 3.78 33 8 −34
119 Extra-nuclear L 4.29 −9 −4 2
Caudate L 4.19 −15 20 −4
Caudate L 4.18 −6 5 −4
Thalamus R 3.89 6 8 2
Caudate R 3.85 −6 11 8
Caudate L 3.60 9 −1 11
Caudate R 3.21 9 −13 17
75 Extra-nuclear L 4.26 −21 −16 −7
Extra-nuclear L 4.02 −24 −19 2
Thalamus L 3.98 −18 −25 5
Midbrain L 3.88 −9 −25 −1
Thalamus L 3.71 −18 −19 −4
Midbrain L 3.55 −12 −31 −4
Extra-nuclear L 3.14 −30 −25 2
121 Middle Temporal
Gyrus
R 4.19 54 −52 8
Middle Temporal
Gyrus
R 4.01 48 −61 8
Superior Temporal
Gyrus
R 3.92 57 −55 23
74 Inferior Frontal Gyrus R 3.92 45 23 17
Inferior Frontal Gyrus R 3.90 39 17 38
Middle Frontal Gyrus R 3.80 39 11 35
Precentral gyrus R 3.72 39 20 26
Middle Frontal Gyrus R 3.29 51 17 17
R= right; L= left; MNI=Montreal Neurological Institute.
Fig. 2. 11.25 mg citalopram minus saline signiﬁcant time× treatment inter-
action at p < 0.001 uncorrected threshold in sagittal view.
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the signiﬁcantly activated brain areas to achieve the ‘optimal set’ of
relationships between investigated variables. Notable relationships
between personality traits and brain areas detected with LASSO
regression included self-consciousness–MCG (RB=0.37),
anxiety–thalamus (RB=0.30) and anxiety–midbrain (RB=0.10).
Fig. 4 shows an adaptive graphical lasso based model with the mean
values of adaptive graphical LASSO coeﬃcients, computed using 100
generated models. For detailed results of LASSO analysis and relevant
relationship between activation changes of brain areas see
Supplementary Table 5.
4. Discussion
Our direct pharmacological challenge study of acute citalopram as a
probe of serotonergic neurotransmission revealed widespread and sig-
niﬁcant activation in several brain areas that are part of the default
mode network (posterior cingulate gyrus, precuneus, angular gyrus,
MTG and parahippocampal gyrus), the visual network (lingual gyrus,
cuneus, fusiform gyrus and middle occipital gyrus), and the sensor-
imotor network (postcentral gyrus). Thus, we successfully applied and
also extended to female participants the previously reported (McKie
et al., 2005) citalopram phMRI method to follow direct regional BOLD
response to serotonergic stimulation while also investigating the eﬀect
of a higher dose. Using a stricter signiﬁcance threshold (pFWE<0.05)
compared to the original study (p < 0.001) in a larger sample we
found a similar pattern of activation. However, some of these activa-
tions including well-known regions with dense serotonergic innerva-
tion, such as the amygdala, and clusters involving the thalamus and
midbrain, showed signiﬁcant activation only at a higher dose. The most
signiﬁcant dose eﬀect of citalopram was detected in the MCG, a key hub
of reﬂexive orientation toward sensory stimuli (Vogt, 2014). In addi-
tion, time-series analysis revealed that the activation pattern travelled
in an occipito-frontal direction suggesting that acute serotonin reuptake
inhibition initially facilitates visual information processing with down-
stream involvement of subcortical motor, frontal executive regions and
threat evaluation in amygdala (Supplementary video).
We also demonstrated that the total BOLD response to citalopram is
associated with neuroticism, a trait-like endophenotype for several
neuropsychiatric disorders and a potent modulator of emotional arousal
and threat processing (Goldstein and Klein, 2014; Kehoe et al., 2012).
By modelling the subscales of neuroticism together with activated brain
areas we demonstrated LASSO-relevant relationships between anxiety
and thalamus, anxiety and midbrain, and self-consciousness and the
MCG. These results further support serotonergic neurotransmission
having an important role in determining neuroticism and therefore
vulnerability to depression, anxiety and pain disorders.
4.1. Brain activation pattern during acute citalopram challenge
PET studies reported low 5HTT levels in most cortical areas except
the limbic lobe and a diverse distribution of diﬀerent 5-HT receptor
types across the whole brain (Saulin et al., 2012; Savli et al., 2012). In
addition, a previous PET/MR study investigating the pharmacological
response to citalopram showed that intravenous administration of 8mg
citalopram over 8min led to 69 ± 7% 5HTT occupancy after the
challenge (Gryglewski et al., 2019). Althougth the dose and timeframe
Fig. 3. BOLD signal changes in MCG after the infusion started in 7.5 mg citalopram minus saline (blue) and 11.25mg citalopram minus saline (red) comparison
showing dose-dependent activation changes over time with error bars indicating standard error (SE).
Fig. 4. Adaptive graphical lasso based
model with the mean values of adaptive
graphical LASSO coeﬃcients, computed
using 100 generated models. The thickness
of lines represents the strength of relation-
ships between variables. Colors: blue – peak
regions, yellow – neuroticism facets from
NEO-P-R, green – other covariates (sex and
age). SelfCo – self-consciousness, Depr –
depression, Vuln – vulnerability, Anx – an-
xiety, AngH – angry hostility, MCG – middle
cingulate gyrus, Thal – thalamus, rMTG –
right middle temporal gyrus, lMTG – left
middle temporal gyrus, LingG – lingual
gyrus, Midb – midbrain, Caud – caudate,
ParaH – parahippocampal gyrus, rFusG –
right fusiform gyrus, lAmy – left amygdala,
rAmy – right amygdala.
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of the citalopram infusion is almost the same as in our study, no cita-
lopram-evoked BOLD responses were observed in the PET/MR study.
The authors suggested that scanner drift might have matched their
occupancy regressors thus obscuring BOLD changes. Correction for drift
in the present study may therefore account for the signiﬁcant changes
in BOLD signal due to citalopram challenge we observed.
Much is known about the distribution of 5HTT and 5-HT receptors
in the human brain that would be engaged by 5-HT release following
citalopram challenge (Savli et al., 2012). The most accepted hypothesis
regarding the eﬀect of SSRIs is that increased synaptic serotonin levels
activate high aﬃnity 5-HT1A inhibitory heteroreceptors on GABA-ergic
inhibitory interneurons and consequentially disinhibit glutamatergic
pyramidal cell activity which is the driver of neurovascular coupling
and the BOLD response (Chilmonczyk et al., 2015; Klaassens et al.,
2015). It is likely that other 5-HT receptors and neurotransmitters in
serotonergic projection areas take part in the observed activation
changes, especially at higher doses. However, in this study we cannot
draw a conclusion on the exact mechanisms behind the observed BOLD
signal changes due the diversity of 5-HT receptor and 5HTT distribution
in diﬀerent brain regions and the complex relationships of 5-HT with
other neurotransmitter systems. Nevertheless, the net cortical disin-
hibition could be the origin of extensive decreases in functional brain
connectivity in resting state networks observed after single oral doses of
SSRIs in several studies (Klaassens et al., 2015, 2017, 2018; Schwarz
et al., 2009; Schaefer et al., 2014).
4.2. Dose eﬀect of acute citalopram challenge
Microdialysis studies demonstrated that the extracellular increase of
serotonin elicited by blockade of 5HTT using SSRIs is dose dependent
(Bel and Artigas, 1992). In addition, a previous phMRI study showed
widespread and dose-dependent BOLD activation changes to acute ci-
talopram treatment in rats (Sekar et al., 2011). In our study, we found
similar widespread brain activation following the higher citalopram
dose that additionally activated brain areas with dense serotonergic
innervation including the midbrain, caudate, and thalamus. Activation
of similar functional networks has been described in rat phMRI studies
following acute i.v. ﬂuoxetine (Schwarz et al., 2007, 2009) where re-
sponses correlated with raphe nuclei activation in the same subcortical
structures as in our study, such as thalamus, caudate and amygdala
(Schwarz et al., 2007). The extended activation might be related to the
quantitative eﬀect of a more potent 5HTT blockade and increased sy-
naptic serotonin content resulting from the higher dose but we could
not exclude that receptors with less aﬃnity for serotonin, such as the
excitatory 5-HT2A receptor, contribute to this eﬀect (Chilmonczyk
et al., 2015; Marek et al., 2003).
The MCG showed a clear signiﬁcant dose-dependent increase in
BOLD signal surviving whole-brain correction. The MCG is a key central
site controlling rapid motoric body orientation response during sensory
information processing and is primarily involved in Go/approach be-
haviour instead of noGo/avoidance response; a process which occurs
before emotional/cognitive assessments of other brain areas (Vogt,
2014). Our study provides evidence of dose-dependent modulation of
MCG activation by serotonergic innervation in the human brain, which
may contribute to the mechanism of antidepressant action and re-
present a potential biomarker for depression and recovery in the light of
previous evidence that this region is involved in the pathomechanism of
unipolar depression and stress-related disorders (Vogt, 2014).
4.3. Acutely increased serotonergic neurotransmission and heightened
arousal
Our group-level analysis indicate that acutely increasing synaptic
serotonin enhances BOLD signal in several brain regions with none
showing whole-brain signiﬁcant decreases in BOLD signal during the
citalopram challenge. The observed pattern of activation shows
similarity with brain activation related to emotional arousal during
threat processing. For example, Farrow and colleagues (Farrow et al.,
2012) demonstrated that skin conductance changes during exposure to
threatening vs harmless stimuli were signiﬁcantly associated with brain
activation in the lingual gyrus, precuneus, MCG, postcentral gyrus, bi-
lateral precentral gyrus/supplementary motor area, medial prefrontal
cortex and thalamus. Increased arousal increases emotion processing
and involves extensive brain areas related to promotion of survival,
such as facilitation of sensory information processing of environmental
triggers, focus of attention to internal and external stimuli, and motoric
orientation towards the source of information (LeDoux, 2012). We
speculate that acute citalopram-induced increases in synaptic serotonin
content produces a brain state similar to increased arousal, despite the
fact that no signiﬁcant pulse rate, blood pressure or arousal symptom
changes were seen at the doses we applied. There is increasing interest
in dysregulation of arousal as a transdiagnostic process (Hegerl and
Hensch, 2014; Huang et al., 2015; Sander et al., 2015) contributing not
only to the pathogenesis of depression (Hegerl et al., 2012) but also to
other psychiatric disorders including anxiety (Domschke et al., 2010)
and chronic pain disorders (Foo and Mason, 2003); indeed arousal has
become a transdiagnostic research domain in the Research Domain
Criteria project (RDoc) (Cuthbert, 2014; Morris and Cuthbert, 2012).
Furthermore, increased arousal in depression (Hegerl et al., 2012;
Schmidt et al., 2016, 2017) may be an important determinant of anti-
depressant treatment outcome, with studies showing that a subgroup of
responders have heightened and faster reduction of arousal during
antidepressant treatment compared to non-responders (Olbrich et al.,
2016; Schmidt et al., 2017). Our ﬁndings suggest there could be a
serotonergic basis to transdiagnostic dysfunctional arousal in psychia-
tric disorders. This could be a fruitful area of further investigation.
4.4. Brain serotonin neurotransmission and neuroticism
Several studies investigated neuroimaging biomarkers of person-
ality traits such as neuroticism, an important endophenotype of de-
pression, anxiety and chronic pain (Wade et al., 1992; Weinstock and
Whisman, 2006). Association between neuroticism and decreased 5-
HT1A receptor binding in several brain regions with the strongest ne-
gative correlation in the hippocampus, superior temporal gyrus and
prefrontal cortex (Hirvonen et al., 2015), and increased 5-HT2A re-
ceptor binding in frontolimbic regions has been reported in previous
PET studies (Frokjaer et al., 2008).
Our study demonstrated an association between neuroticism and
BOLD activation during the lower citalopram dose (7.5 mg) in the
thalamus and midbrain with correlation between the anxiety compo-
nent of neuroticism and BOLD activation changes in the thalamus and
midbrain. This is in line with a previous neuroimaging study that
showed a positive correlation between neuroticism and 5-HTT binding
in the thalamus (Takano et al., 2007), but a similar study found no such
association (Kalbitzer et al., 2009) while another showed an association
between 5-HTT binding and neuroticism but with opposite directions in
males and females (Tuominen et al., 2017). The positive association of
anxiety with increased functional serotonergic function is compatible
with the increased anxiety that commonly occurs early in SSRI therapy
which is probably mediated by excessive 5-HT2C function with tol-
eration occurring after repeated treatment (Deakin, 2013; Deakin and
Graeﬀ, 1991).
The region that showed a signiﬁcant dose eﬀect in the MCG in our
study also showed a correlation with the self-consciousness facet of
neuroticism. A previous study reported decreased functional coupling
between the MCG and amygdala during emotion suppression associated
with self-consciousness (Chen et al., 2017). Several studies have found
that the function of an area corresponding to the MCG may be related to
neuroticism (DeYoung et al., 2010; Kano et al., 2014), but interpreta-
tion is hindered by the lack of standard nomenclature, since it is
sometimes labelled as anterior or posterior cingulate cortex (Kumari
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et al., 2007; Tzschoppe et al., 2014).
Altogether, our results, consistent with previous neuroimaging stu-
dies, provide evidence of a relationship between neuroticism and
function of the thalamus, midbrain, and MCG, and indicate that this
relationship is mediated by the functional state of serotonin neuro-
transmission. This may also shed further light on the therapeutic eﬀect
of SSRIs, as previous studies have shown that neuroticism may have a
role in the eﬀect of SSRI treatment outcome in depressed patients be-
yond improved mood (Quilty et al., 2008; Tang et al., 2009). We
speculate that SSRIs could bring about positive neuroplastic changes in
neural circuits related to neuroticism that might be necessary to sta-
bilise remission in neuropsychiatric disorders where neuroticism is an
important risk factor.
5. Limitations
Our study has some limitations. We included only healthy partici-
pants and the ﬁndings need to be related to changes in patients with
depression, anxiety and chronic pain disorders. In addition, the sample
size for the dose-response is small and administration was not blinded
for the 11.25mg citalopram challenge. Nevertheless, we found highly
signiﬁcant activation changes with 9 participants in the 11.25mg
minus saline comparison occurring in regions with well-known ser-
otonergic innervation, consistent with previous research. We did not
measure physiological or performance measures of arousal and clearly
the possible relationship to regional brain eﬀects of citalopram chal-
lenge is speculative. However, the brain regions that responded with
increased BOLD signal were similar to brain activation related to
emotional arousal during threat processing. Nevertheless, our in-
ferences need direct tests in future studies designed speciﬁcally to
measure brain activation changes to external stressors and its relations
to citalopram challenge.
6. Conclusion
Acute i.v. citalopram administration not only elicited dose depen-
dent increasing brain activation in several regions involved in ser-
otonergic neurotransmission and part of the default mode, visual and
sensorimotor networks, but individual response diﬀerences were asso-
ciated with neuroticism. Activated brain regions were similar to those
involved in arousal and as neuroticism entails a tendency for heigh-
tened stress reactivity, our results could reﬂect modulating eﬀect of
serotonin to process environmental stressors, which may also play a
role in therapeutic eﬀects of SSRIs.
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